Navigation Links
Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study
Date:2/7/2008

CHAPEL HILL, N.C., Feb. 7 /PRNewswire/ -- Falling stock prices, devaluing dollar, soaring gas prices, and the slumping real estate market are just a few of the symptoms of the recession hitting the U.S. economy. While a recession will impact all industries, it may have a deeper impact on pharma and biotech companies as they have already been dealing with increasing pricing and regulatory pressures and decreasing numbers of newly approved therapies. Given the current environment, it is imperative for companies to maintain the appropriate mix of budgets and staffing to meet corporate objectives.

The current report, U.S. Pharmaceutical Budget and Staffing Excellence: Benchmarking the Resources Required to Drive Productivity and Growth, can be an invaluable resource allowing pharmaceutical and biotech executives to critically assess key business functions and resources against thirty-six top pharma and biotech companies. The rich metrics contained in this comprehensive report emanate from survey responses from staffing executives at such elite pharmaceutical and biotech companies as Abbott Labs, AstraZeneca, Bristol-Myers Squibb, J&J, Eli Lilly GlaxoSmithKline, Merck, Novartis, Pfizer, Roche and Sanofi-Aventis.

Executive insight across seven critical functional areas, including:

* Marketing Operations

* Marketing Services

* Sales Support

* Managed Care

* State & Government Affairs

* Finance

* Legal and Compliance

Sampling of the key findings harnessed from the report include:

* Marketing Services groups support an average of 7.8 brands with 6.7 FTEs

allocated per brand promoted

* Sales Support groups allocate approximately $460,000, including labor,

overhead and outsourcing, per sales support FTE

* Managed Care groups report an average of 18 FTEs allocated to Customer

Marketing Strategy

* Finance budgets as a percentage of sales average 1.33%


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Pinnacle Biologics, a,private, full-service pharmaceutical and biotech ... agreement with pharmexx to expand sales,support activities in ... of the,agreement were not disclosed., Viren Grover, ... to conclude this agreement with pharmexx, which allows ...
... ON, July 9 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... and six months ended May 31, 2008. All dollar ... At May 31, 2008, our cash and cash ... 29, 2008., The net loss for the second ...
... Evaluate Treatment of Coronary Artery Disease ... Patients in Real-World Setting, ABBOTT PARK, ... V(TM) USA post-approval study, with six,hospital centers already recruiting and enrolling ... the XIENCE V(TM),Everolimus Eluting Coronary Stent System. The XIENCE V USA ...
Cached Biology Technology:Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2Vasogen Announces Second Quarter 2008 Results 2Vasogen Announces Second Quarter 2008 Results 3Vasogen Announces Second Quarter 2008 Results 4Vasogen Announces Second Quarter 2008 Results 5Vasogen Announces Second Quarter 2008 Results 6Vasogen Announces Second Quarter 2008 Results 7Vasogen Announces Second Quarter 2008 Results 8Vasogen Announces Second Quarter 2008 Results 9Vasogen Announces Second Quarter 2008 Results 10Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 2Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 3Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent 4
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/29/2014)... academics in the University of Bristol,s Nutrition and Behaviour ... calories into account when planning meals. , The research, ... of Ingestive Behavior Conference (SSIB 2014) in Seattle, USA ... we do. , The team was led by Professor ... Experimental Psychology. , As part of a Biotechnology and ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... BETHESDA, MD August 23, 2007 On August 16, the ... blood-thinner warfarin, sold under the brand name Coumadin. The new ... that may be safer for patients with variations in two ... through genetic testing, which may be a useful tool in ...
... Optics 2007 (FiO), the 91st Annual Meeting of the ... 16-20 in San Jose, Calif., alongside Laser Science XXIII, ... of Laser Science. Reporters interested in obtaining a ... at 202.416.1437, cmorri@osa.org . FiO RESEARCH ...
... system designed for brain tumor therapy has shown promising ... devised by University of Nottingham scientists. The project, conducted ... Human Development, will be featured in the September issue ... cancers is particularly difficult for a number of reasons, ...
Cached Biology News:American College of Medical Genetics responds to new FDA labeling decision for warfarin 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Novel 3-D cell culture model shows selective tumor uptake of nanoparticles 2
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... The standard of the Axima range, ... high mass accuracy, resolution, sensitivity and ... with both linear and reflectron time-of-flight ... reflectron enables the generation of seamless ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: